Kolefas joins the international pharmaceutical company after more than 25 years spent on Wall Street’s buyside where he managed both mutual funds and institutional equities at TIAA Investments, Jennison Associates, Loomis Sayles, Mackay-Shields and Bank of New York.
Kolefas also boasts considerable industry experience as a chemical engineer and corporate development officer at Engelhard/BASF.
“Tom Kolefas brings a wealth of expertise to our company,” said Grigorios Siokas, CEO of Cosmos in a statement. “He has a track record for success in identifying value within the mid-cap space. We look forward to his contribution as we position ourselves for continued growth.”
For his part, Kolefas is eager to come on board at Cosmos and advance its business efforts.
“Cosmos has a well-thought out, balanced strategy of organic growth, market share gains, new product introductions and acquisitions to capitalize on the growth in the drug, nutraceutical, vitamin and Europe-only cannabis end-markets in Europe, the U.S. and ultimately, the rest of the world," Kolefas said in a statement.
Cosmos Holdings Inc. is an international pharmaceutical company that specializes in acquiring, developing, and commercializing medicines. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and in the UK.
Cosmos shares closed up 8.3% to hit $3.00 on Thursday.
Contact Ellen Kelleher at [email protected]